Pomezia, Italy, November 19th 2018 – IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).
IRBM signs collaboration agreement with Merck & Co., Inc, Kenilworth, NJ, USA to advance peptide therapeutics
4th September 2018
Pomezia, Italy – IRBM, today announced a new agreement in the peptide therapeutics area with Merck & Co. Inc., Kenilworth NJ USA, known as MSD outside the United States and Canada, continuing their long-standing history of collaboration that began in 2010.
Pomezia, Italy, June 19, 2018 – IRBM will be providing services using human induced pluripotent stem cells (hiPSCs) based on the iPS cell-related patents that have been sublicensed to iPS Academia Japan by Kyoto University. Continue Reading
Pomezia, Italy, May 31, 2018 – IRBM, a global Contract Research Organization, has recruited two new members of staff as part of its global growth strategy. Carlo Toniatti, M.D., Ph.D., has been appointed as the Chief Scientific Officer, bringing more than two decades of drug development and discovery experience to the role where he will oversee scientific strategy, and Heidi Kingdon-Jones has been recruited as the Global VP of Sales and Marketing, to drive forward IRBM’s continued global expansion. Continue Reading